NCT02710500View on ClinicalTrials.gov

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Dysferlinopathy
Interventions
DRUG

rAAVrh74.MHCK7.DYSF.DV

Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.

Trial Locations (1)

43205

Nationwide Children's Hosptial, Columbus

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT02710500 - rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies | Biotech Hunter | Biotech Hunter